Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 A.M. ET. This conference will take place from September 13-15, 2021. Investors can access the live presentation via a webcast link provided in the press release. Acurx focuses on developing novel antibiotics for challenging infections, targeting Gram-positive bacteria such as Clostridioides difficile and MRSA.
- None.
- None.
STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
Investors may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below.
Event: | H.C. Wainwright 23rd Annual Global Investment Conference |
Date: | September 13-15, 2021 |
Session Start Date | |
and Time: | 7 a.m. ET on September 13, 2021 |
Webcast: | https://journey.ct.events/view/75943fdc-2093-4e66-a80a-c6d6e6f9ed6a |
Archived: | 90 days |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of August 30, 2021. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-2021-301365066.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
When will Acurx Pharmaceuticals present at the H.C. Wainwright 23rd Annual Global Investment Conference?
What is the focus of Acurx Pharmaceuticals?
What types of bacteria does Acurx target?
How can investors access the Acurx Pharmaceuticals presentation?
What are the dates for the H.C. Wainwright Global Investment Conference?
